0.00
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Syros Pharmaceuticals
Its shares trade under the ticker SYRS. It has been listed since 30 June 2016. In the fiscal year to 31 December 2023, it reported revenue of $9.9m and a net loss of $164.6m. At that date it held total assets of $168.2m and shareholders' equity of $16.7m.
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2016-06-30. The firm is focused on redefining the power of small molecules to control the expression of genes. The company is focused on developing treatments for cancer and diseases resulting from mutations of a single gene (monogenic diseases) and building a pipeline of gene control medicines. Its product candidates include SY-1425, SY-5609 and SY-2101. SY-1425 is a selective retinoic acid receptor alpha (RAR), agonist that is being evaluated in combination with azacytidine, used to treat acute myeloid leukemia (AML). SY-5609 is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) that is being evaluated in the dose escalation portion in patients with select advanced solid tumors. SY-2101 is an oral form of arsenic trioxide (ATO) being developed for the treatment of AML.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Jun 2016
- Employees
- 83
- Website
- syros.com ↗
Leadership
Pay as last reported
- Ms. Kristin StephensChief Development Officer
- Mr. Gerald QuirkDirector, since 2016$1.5m
- Ms. Hannah DeresiewiczIR Contact Officer, since 2017
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 78
- Environment
- 84
- Social
- 83
- Governance
- 66
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Syros Pharmaceuticals focuses on gene control therapies for cancer and monogenic diseases with 83 employees.
- SY-1425 targets acute myeloid leukemia (AML) in combination with azacytidine for effective treatment.
- SY-2101 is an oral arsenic trioxide formulation for AML treatment, advancing gene control medicine pipeline.
Weaknesses
- Syros Pharmaceuticals has only 83 employees, indicating limited workforce capacity.
- The company's product pipeline includes only three candidates: SY-1425, SY-5609, and SY-2101.
- Syros Pharmaceuticals has a single focus on gene control therapies without diversification.
Opportunities
- Expanding the use of SY-1425 in combination therapy for AML treatment options.
- Developing SY-5609 for advanced solid tumors could open new market segments.
- SY-2101's oral formulation may improve patient adherence for AML treatment.
Threats
- Competition from other biotechnology firms in the Health Care sector for gene control therapies.
- Regulatory challenges in developing new therapies for cancer and monogenic diseases.
- Market risks associated with the limited number of product candidates in the pipeline.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.